Trial Profile
Phase IV study to evaluate the safety and efficacy of the treatment of hyperglycemia with Gla-300 in basal-bolus regimen in hospitalised T2D patients poorly controlled with basal insulin and/or non-insulin treatments and therapy intensification at discharge with basal insulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COBALTA
- Sponsors Sanofi
- 28 Jul 2018 Status changed from recruiting to completed.
- 21 Apr 2016 New trial record